• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

philip.thompson@unimelb.edu.au

Credentials


Position
Honorary Conjoint Principal Fellow
The Sir Peter MacCallum Department of Oncology
ORCID

0000-0003-2086-6031

A/Prof Philip Thompson

Honorary Conjoint Principal Fellow
The Sir Peter MacCallum Department of Oncology

43 Scholarly works
0 Projects

HIGHLIGHTS

  • 2026

    Journal article

    NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy.
    DOI: 10.1182/bloodadvances.2026020243
  • 2026

    Journal article

    Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma
    DOI: 10.1182/bloodadvances.2025016646
  • 2026

    Journal article

    Ibrutinib with venetoclax in patients with relapsed/refractory chronic lymphocytic leukemia: A phase II study.
    DOI: 10.1158/2643-3230.BCD-25-0345
  • 2026

    Journal article

    Balancing gains and pains: infections in the bispecific era
    DOI: 10.1080/10428194.2025.2586082
  • 2025

    Journal article

    Epcoritamab combinations demonstrate promising efficacy in patients (pts) with Richter transformation (RT): First results from arms 2B (epcor lenalidomide [LEN]) and 2C (epcor R-CHOP) of the phase 1b/2 EPCORE CLL-1 trial
    DOI: 10.1182/blood-2025-1015
  • 2025

    Journal article

    Prognostic Implication of Karyotypic Evaluation in Patients With Richter Transformation in the Modern Era
    DOI: 10.1002/ajh.27760
  • 2024

    Journal article

    Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma
    DOI: 10.1182/blood-2024-205671
Philip Thompson

RECENT SCHOLARLY WORKS

  • 2024

    Journal article

    Bridging Radiotherapy to Axicabtagene Ciloleucel (axi-cel) Is Associated with Favourable Outcomes for Large B-Cell Lymphoma (LBCL) in Third-Line and Beyond: An Australian Single-Centre Real-World Experience
    DOI: 10.1182/blood-2024-209767
  • 2024

    Journal article

    Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study
    DOI: 10.1016/S2352-3026(24)00172-8
  • 2024

    Journal article

    Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions
    DOI: 10.1182/blood.2023023388

We acknowledge and pay respect to the Traditional Owners of the lands upon which our campuses are situated

Read about our commitment to reconciliation  

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia


View all Campus locations  
facebookIconlinkedinIconinstagramIcontwitterIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy  |  VaxFACTS

CRICOS number: 00116K     ABN: 84 002 705 224